Organization Overview
Alternative names
alemtuzumab (campath) (1 trial)
allogeneic hematopoietic stem cells (Hemacord) (1 trial)
anagrelide (agrylin) (1 trial)
autologous hematopoietic stem cells (1 trial)
bleomycin (blenoxane) (2 trials)
chlorambucil (Leukeran) (2 trials)
cytarabine (cytosar-u) (10 trials)
dacarbazine (dtic-dome) (2 trials)
daunorubicin (cerubidine) (3 trials)
doxorubicin (Doxil) (9 trials)
etoposide (vepesid) (2 trials)
fludarabine (fludara) (8 trials)
gemcitabine (gemzar) (1 trial)
90y-dota-epratuzumab (1 trial)
acalabrutinib (calquence) (1 trial)
autologous mononuclear stem cell (1 trial)
azacitidine (vidaza) (2 trials)
bendamustine (treanda) (4 trials)
Aggression (Phase 2)
Hodgkin Disease (Phase 3)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 3)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Peripheral (Phase 3)
Primary Myelofibrosis (Phase 2)
Recurrence (Phase 1)
Thrombocythemia, Essential (Phase 3)
Thrombocytosis (Phase 3)
Waldenstrom Macroglobulinemia (Phase 3)